New roles of osteoblasts involved in osteoclast differentiation

Teruhito Yamashita, Naoyuki Takahashi, Nobuyuki Udagawa

Abstract
Bone-resorbing osteoclasts are formed from a monocyte/macrophage lineage under the strict control of bone-forming osteoblasts. So far, macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear factor-κB ligand (RANKL), and osteoprotegerin (OPG) produced by osteoblasts play major roles in the regulation of osteoclast differentiation. Recent studies have shown that osteoblasts regulate osteoclastogenesis through several mechanisms independent of M-CSF, RANKL, and OPG production. Identification of osteoclast-committed precursors in vivo demonstrated that osteoblasts are involved in the distribution of osteoclast precursors in bone. Interleukin 34 (IL-34), a novel ligand for c-Fms, plays a pivotal role in maintaining the splenic reservoir of osteoclast-committed precursors in M-CSF deficient mice. IL-34 is also able to act as a substitute for osteoblast-producing M-CSF in osteoclastogenesis. Wnt5a, produced by osteoblasts, enhances osteoclast differentiation by upregulating RANK expression through activation of the non-canonical Wnt pathway. Semaphorin 3A produced by osteoblasts inhibits RANKL-induced osteoclast differentiation through the suppression of immunoreceptor tyrosine-based activation motif signals. Thus, recent findings show that osteoclast differentiation is tightly regulated by osteoblasts through several different mechanisms. These newly identified molecules are expected to be promising targets of therapeutic agents in bone-related diseases.

© 2012 Baishideng. All rights reserved.

Key words: Osteoclast; Osteoblast; Receptor activator of nuclear factor-κB ligand; Wnt5a; Semaphorin 3A; Interleukin 34

INTRODUCTION
Bone is continuously destroyed and reformed in vertebrates to maintain bone volume and calcium homeostasis. Osteoblasts and osteoclasts are specialized cells responsible for bone formation and bone resorption, respectively. Osteoblasts produce bone matrix proteins and take charge of mineralization of the tissue. Osteoclasts are multinucleated cells responsible for bone resorption. It has been well established that osteoclasts are formed from monocyte/macrophage lineage precursors under the strict regulation of osteoblasts, osteocytes, and bone marrow stromal cells (referred to as “osteoblasts” in this review).

Osteoblasts express two cytokines essential for osteoclast differentiation, macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL), and osteoprotegerin (OPG) produced by osteoblasts play major roles in the regulation of osteoclast differentiation. Recent studies have shown that osteoblasts regulate osteoclastogenesis through several mechanisms independent of M-CSF, RANKL, and OPG production. Identification of osteoclast-committed precursors in vivo demonstrated that osteoblasts are involved in the distribution of osteoclast precursors in bone. Interleukin 34 (IL-34), a novel ligand for c-Fms, plays a pivotal role in maintaining the splenic reservoir of osteoclast-committed precursors in M-CSF deficient mice. IL-34 is also able to act as a substitute for osteoblast-producing M-CSF in osteoclastogenesis. Wnt5a, produced by osteoblasts, enhances osteoclast differentiation by upregulating RANK expression through activation of the non-canonical Wnt pathway. Semaphorin 3A produced by osteoblasts inhibits RANKL-induced osteoclast differentiation through the suppression of immunoreceptor tyrosine-based activation motif signals. Thus, recent findings show that osteoclast differentiation is tightly regulated by osteoblasts through several different mechanisms. These newly identified molecules are expected to be promising targets of therapeutic agents in bone-related diseases.

© 2012 Baishideng. All rights reserved.

Key words: Osteoclast; Osteoblast; Receptor activator of nuclear factor-κB ligand; Wnt5a; Semaphorin 3A; Interleukin 34
κB ligand (RANKL)[1,2] (Figure 1). Experiments using an osteoporotic op/op mouse model have established that the osteoblast product M-CSF is crucial for osteoclast differentiation[3]. The M-CSF gene in op/op mice cannot code functionally active M-CSF protein[4]. Administration of recombinant M-CSF to op/op mice restores impaired bone resorption[5]. RANKL is a member of the tumor necrosis factor (TNF) family (TNF superfamily member 11)[6,7]. The expression of RANKL by osteoblasts is inducible. Osteoblasts express RANKL as a membrane-associated form in response to stimuli of bone resorption-stimulating factors such as 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], parathyroid hormone, prostaglandin E2, and interleukin (IL)-11[8]. Osteoclast precursors express c-Fms (M-CSF receptor) and RANK (RANKL receptor) and differentiate into osteoclasts in the presence of M-CSF and RANKL. RANKL stimulation strongly induced the expression of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), a pivotal transcription factor for osteoclast development, in osteoclast precursors[8,9]. Osteoblasts also produce osteoprotegerin (OPG, TNFRSF11B), a soluble decoy receptor for RANK[9,10]. OPG inhibits osteoclastogenesis by blocking the RANKL-RANK interaction[11,12]. Both RANKL-deficient mice[11] and RANK-deficient mice[12] develop severe osteopetrosis with no osteoclasts in bone. In contrast, OPG-deficient mice[13,14] exhibit severe trabecular and cortical bone porosity with enhanced osteoclastic bone resorption.

Discovery of the RANKL-RANK signal in osteoclastogenesis has clarified the cause of some bone diseases in humans. Loss-of-function mutations in the OPG gene cause Juvenile Paget’s disease and idiopathic hyperphosphatasia[13,14]. Gain-of-function mutations in the RANK gene induce familial expansile osteolysis, familial Paget’s disease of bone, and expansile skeletal hyperphosphatasia[15]. Osteopetrosis due to few osteoclasts is caused by loss-of-function mutations in the RANK gene[16] and RANKL gene[17]. The phenotypes of these bone diseases in humans support the concept that RANKL expressed by osteoblasts stimulates osteoclast differentiation of precursors through the receptor RANK. Thus, the RANKL-RANK axis is the central pathway for osteoclastogenesis. Recent in vivo studies have also shown that osteoblasts regulate osteoclastogenesis through several mechanisms independent of M-CSF, RANKL and OPG production.

In this review article, we focus on the new roles of osteoblasts in osteoclast differentiation. First, osteoblasts are involved in the distribution of osteoclast precursors in bone. Second, osteoblast-producing M-CSF can be replaced by IL-34 in osteoclastogenesis. Third, osteoblasts produce Wnt5a, which enhances osteoclast differentiation through the upregulation of RANK expression. Lastly, osteoblast-producing semaphorins regulate osteoclast formation in the presence of RANKL signaling. Overall, these findings remind us of the importance of osteoblasts in osteoclast development.
cycle-arrested quiescent osteoclast progenitors (QOPs) (Figure 2). QOPs were also isolated from bone marrow and peripheral blood. Bone marrow-derived QOPs failed to express macrophage-associated markers such as F4/80 and CD11b. Bone marrow-derived QOPs showed no phagocytic activity and did not proliferate in response to M-CSF. They differentiated into osteoclasts, but not into dendritic cells. Therefore, it has been concluded that QOPs are committed osteoclast precursors.

**ROLE OF IL-34 IN OSTEOCLASTOGENESIS**

Recently, Lin et al. discovered IL-34 as a new ligand for c-Fms. The amino acid sequence of IL-34 was quite different from that of M-CSF, but IL-34 promoted macrophage colony formation similar to M-CSF. Chihara et al. (2006) reported that M-CSF and IL-34 used different signaling to induce the expression of several chemokines and suggested that they differentially regulated macrophage function. However, IL-34 as well as M-CSF, in combination with RANKL, induced osteoclast formation in mouse and human cell culture systems. IL-34 was specifically expressed in splenic tissues, predominantly in the red pulp region. Recently, Nakamichi et al. (2008) showed that RANK and c-Fms double-positive QOPs did not exist in bone, but existed in the spleen of op/op mice (Figure 2). IL-34 was highly expressed in vascular endothelial cells in the spleen. Vascular endothelial cells in bone also expressed IL-34, but its expression level was much lower than that in the spleen, suggesting a role of IL-34 in the splenic maintenance of QOPs. Indeed, removal of the spleen (splenectomy) completely blocked M-CSF-induced osteoclast formation in op/op mice. Osteoclasts appeared in aged op/op mice with up-regulation of IL-34 expression in the spleen and bone. Splenectomy also blocked the age-associated appearance of osteoclasts. These results suggest that IL-34 plays a pivotal role in maintaining the splenic reservoir of QOPs, which are transferred to bone in response to M-CSF administration in op/op mice (Figure 2). Recently, sphingosine-1-phosphate, a lipid mediator regulating immune cell trafficking, was shown to regulate the migration of osteoclast precursors. Osteoclasts appear to help homing of QOPs to bone. Thus, osteoblasts determine the distribution of QOPs, which decide the correct sites of osteoclast formation.

**WNT5A-RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 2 SIGNALING AND OSTEOCLASTOGENESIS**

Immunohistochemical analysis revealed that RANK expression in osteoclast precursors was much stronger than that in bone marrow and the spleen. Recently, Maeda et al. (2009) reported that Wnt5a produced by osteoblasts promoted RANK expression in osteoclast precursors (Figure 3). Wnt binds to two distinct receptor complexes: a complex of Frizzled and low density lipoprotein receptor-related protein 5/6 (LRP5/6) and another complex of Frizzled and receptor tyrosine kinase-like orphan receptors (Rors). The binding of Wnts to these Wnt receptors activates two classes of signaling pathways: a β-catenin-dependent (canonical) pathway and β-catenin-independent (non-canonical) pathway. The importance of the canonical pathway in bone metabolism has been emphasized by the identification of a link between bone mass and mutations in the LRP5 gene. Loss-of-function mutations in LRP5 reduced the number of osteoblasts and caused osteoporosis. Glass et al. (2000) developed mice expressing a stabilized form of β-catenin in osteoblasts (β-catenin mutant mice) and reported that β-catenin mutant mice developed severe osteoporosis due to the up-regulation of OPG expression. Thus, Wnt/β-catenin signaling is crucial in osteoblastogenesis and osteoclastogenesis. However, the role of the non-canonical Wnt pathway in bone resorption remains largely unknown.

Maeda et al. (2009) showed that Wnt5a receptor tyrosine kinase-like orphan receptor 2 (Ror2) signaling between osteoblasts and osteoclast precursors enhanced osteoclastogenesis. Ror2-deficient mice exhibited impaired osteoclastogenesis. A deficiency in Wnt5a, a ligand of Ror2, caused a similar defect in mice. Osteoblasts expressed Wnt5a, while osteoclast precursors expressed Ror2, a co-receptor of Wnt5a. Wnt5a enhanced RANK expression in osteoclast precursors through co-receptor Ror2 signaling. RANK promoter-driven luciferase activ-
ty was upregulated by Wnt5a-Ror2 signaling via the c-Jun N-terminal kinase pathway (Figure 3). Wnt5a-induced recruitment of c-Jun to Sp1 sites up-regulated RANK expression in osteoclast precursors.

As described above, QOPs detected on bone surfaces strongly express RANK. Wnt5a secreted by osteoblasts appears to be involved in the up-regulation of RANK expression in QOPs through Ror2. The up-regulation of RANK by Wnt5a-Ror2 signals in osteoclast precursors must lower the threshold for RANKL-induced osteoclastogenesis. Atkins et al. showed that human peripheral blood monocytes expressing high surface levels of RANK were capable of responding rapidly to RANKL stimulation. Under physiological conditions, the up-regulation of RANK expression in osteoclast precursors must be an important requirement for RANKL-induced osteoclastogenesis.

Figure 3  Role of Wnt5a-receptor tyrosine kinase-like orphan receptor 2 signaling in osteoclast precursors. Wnt5a produced by osteoblasts up-regulates RANK expression in osteoclast precursors through Ror2. Wnt5a up-regulates RANK expression through the recruitment of c-Jun to Sp1 sites of the RANK promoter. The up-regulation of RANK expression in osteoclast precursors increases their sensitivity to RANK ligand. JNK: c-Jun N-terminal kinase.

IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF SIGNALS AND SEMAPHORIN 3A

Koga et al. showed for the first time that osteoclastogenesis induced by RANKL also requires co-stimulatory receptor signaling through adaptors containing immunoreceptor tyrosine-based activation motifs (ITAMs), such as Fc receptor common γ (FcγR) and DNAX-activating protein of 12 kDa (DAP12). RANK and ITAM signaling cooperated to induce NFATc1, the master transcription factor for osteoclastogenesis. FcγR and DAP12 are adaptor molecules that associate with immunoglobulin-like receptors such as osteoclast-associated receptor (OSCAR) and triggering receptor expressed on myeloid cells 2 (TREM-2). OSCAR uses FcγRγ, while TREM-2 associates with DAP12. Koga et al. showed that deficiencies in both FcγRγ and DAP12 caused osteopetrotic phenotypes in mice. Because this pathway is crucial for the robust induction of NFATc1 that leads to osteoclastogenesis, these signals are called co-stimulatory signals for RANK in osteoclastogenesis. Recently, Barrow et al. reported that OSCAR bound to a specific motif of collagen and stimulated osteoclastogenesis. These series of experiments have established a new research area called “osteoimmunology”.

Recently, Hayashi et al. reported that semaphorin 3A (Sema3A) produced by osteoblasts suppressed osteoclast differentiation (Figure 4). Sema3A, a secreted axon guidance molecule, is highly expressed by osteoblasts. Neurophilin-1 (Nrp1), the receptor of Sema3A, is expressed by osteoclast precursors. Nrp1 usually forms a receptor complex with Plexin-A1 in bone marrow macrophages of osteoclast precursors. Using Plexin-A1-deficient mice, Takegahara et al. previously showed that Plexin-A1 interacted with TREM-2 and DAP12 to form the receptor complex for Sema6D, a transmembrane semaphorin. Sema6D stimulated osteoclast differentiation through the receptor complex Pleixn-A1/TREM-2/DAP12 in osteoclast precursors through ITAM signaling (Figure 4). These findings suggest that the Sema3A–Nrp1 axis inhibits osteoclast differentiation by sequestering Plexin-A1 from TREM-2 so as to suppress ITAM signaling. Sema3A is a new therapeutic agent in bone and joint diseases.

THERAPEUTIC TARGETS IN THE OSTEOBLAST-OSTEOCLAST INTERACTION

Secreted OPG acts as a decoy receptor of RANKL to compete with RANK on the surface of osteoclast lineage cells. OPG is expressed in osteoblasts and inhibits both osteoclast formation and function. Therefore, biological agents such as an antibody against RANKL have been developed and successfully suppress bone loss. Denosumab, an anti-RANKL antibody, has achieved the most success in the treatment of osteoporosis, tumor-related bone disorders, and arthritis.
Expression levels of Wnt5a and frizzled 5 are higher in the synovial tissue of rheumatoid arthritis (RA) patients than in those of osteoarthritis patients. Wnt5a stimulates the production of pro-inflammatory cytokines such as IL-6 and IL-8 in synoviocytes. Treatment of RA patient-derived synoviocytes with antibodies against frizzled 5, one of the receptors for Wnt5a, diminished the production of RANKL. These findings suggest that Wnt5a promotes pro-inflammatory cytokine production and enhances bone resorption through the production of RANKL in the pathogenesis of RA. In addition, Ror2, another receptor for Wnt5a, is expressed in osteoclast progenitors and co-stimulated non-canonical Wnt signaling. Wnt5a enhanced osteoclast formation in mouse bone marrow macrophage cultures. Administration of glutathione-S-transferase-fused soluble Ror2 restored bone destruction caused by collagen-induced arthritis in mice. These results suggest that Wnt5a is involved in bone destruction in chronic inflammatory diseases. Molecules involved in non-canonical Wnt signaling may be therapeutic targets for the treatment of patients suffering from RA and periodontitis.

The finding of Sema3A has invented a new concept that osteoblasts themselves express a bifunctional factor that induces osteoblastogenesis and inhibits osteoclastogenesis. Sema3A may inhibit bone loss without affecting the coupling system between osteoblasts and osteoclasts. Takayanagi and his colleagues demonstrated that administration of recombinant Sema3A increases bone volume and expedites bone regeneration in osteoporotic mice established by ovariectomy. Thus, Sema3A is a promising anabolic factor possessing an inhibitory activity on bone resorption.

In conclusion, the discovery of the RANKL-RANK interaction opened a new area in bone biology focusing on the molecular mechanisms of osteoclast development and function. This series of experiments concerning the RANKL-RANK interaction have established the concept that osteoblasts, through the expression of RANKL and M-CSF, tightly regulate the development of osteoclasts. Recent in vivo studies also indicate other aspects of osteoblasts in the regulation of osteoclastogenesis. Osteoblasts are involved in the decision of the place for osteoclast formation through taking care of osteoclast precursors. Osteoblasts produce some ligands for immunoglobulin-like receptors to induce ITAM-mediated co-stimulatory signals. Osteoblasts also produce Wnt5a, which stimulates RANK expression in osteoclast precursors though co-receptor Ror2 signaling. The up-regulation of RANK by Wnt5a-Ror2 signals in osteoclast precursors must enhance the sensitivity of QOQPs to RANKL. Osteoblasts also produce Sema3A, which inhibits ITAM signals in osteoclast precursors. These findings provide a new concept that osteoblasts play several roles as an omnipotent conductor in osteoclastogenesis. In conformity with the new concept, we must come back to the osteoblast, which may be a promising target for therapeutic agents in the regulation of bone resorption in the near future.

REFERENCES

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2010; 423: 337-342
2. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endo Rev 1999; 20: 345-357
3. Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993; 91: 257-263
4. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345: 442-444
5. Felix R, Cecchini MG, Fleisch H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990; 127: 2592-2594
6. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu Y, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombo A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins J, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarris I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176

Takahayashi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshiha S, Hauria I, Isobe M, Yokokhi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrates RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901

Yasuda H, Shima N, Nakagawa N, Mochizuki SL, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identification of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1529-1537

Kong YY, Yoshida H, Sarris I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Kho W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPG/IL-1 receptor antagonist (OPG-IR) is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323

Li J, Sarris I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik PJ, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008; 320: 807-811

Chihara T, Suzu S, Hassan R, Chutitiwongchai N, Hiyoshi M, Motoyoshi K, Kimura F, Okada S. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ 2010; 17: 1917-1927

Chen Z, Buki K, Vatariansiemi J, Gu G, Väntänen HK. The critical role of IL-34 in osteoclastogenesis. PLoS One 2011; 6: e18689

Nakamichi Y, Mizoguchi T, Araiz, Kobayashi Y, Sato M, Penninger JM, Yasuda H, Kato S, DeLuca HF, Suda T, Udagawa N, Takahashi N, Spleen as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice. Proc Natl Acad Sci USA 2012; 109: 10006-10011

Ishii M, Egen JC, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, Proia RL, Germain RN. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009; 458: 524-528

Arai A, Mizoguchi T, Harada S, Kobayashi Y, Nakamichi Y, Yasuda H, Penninger JM, Yamada K, Udagawa N, Takahashi N. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. J Clin Cell Sci 2012; 125: 2910-2917

Maeda K, Kobayashi Y, Udagawa N, Uchida S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012; 18: 405-412

Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006; 281: 22429-22435

Gong Y, Skee RB, Fukai N, Rawadi G, Roman-Roman S, Regn A, Wang Y, Cundy T, Glorieux FH, Lev D, Zacharin M, Oedke K, Marcelino J, Suwairi W, Heeger S, Sabatagos K, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch A, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Fioe E, Halbrand ML, Hall B, Hennekam RC, Hirte E, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschutter A,
LaCombe D, Lambert M, Lemyre E, Leteboer T, Petelton L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hol W, Vinkula M, Votruja M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107: 513-523

32 Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751-764

33 Atkins GJ, Kostakis P, Vincent C, Houchins JP, Findlay DM, Evdokiou A, Zannettino AC. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006; 21: 1339-1349

34 Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004; 428: 758-763

35 Barrow AD, Raynal N, Andersen TL, Slatter DA, Bihan D, Pugh N, Cellia M, Kim T, Rho J, Negishi-Koga T, Delaisse JM, Takayanagi H, Lorenzo J, Colonna M, Farndale RW, Choi Y, Trowsdale J. OSCAR is a collagen receptor that co-stimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest 2011; 121: 3505-3516

36 Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292-304

37 Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. Nature 2012; 485: 69-74

38 Takegahara N, Takamatsu H, Toyofuku T, Tsujimura T, Okuno T, Yukawa K, Mizui M, Yamamoto M, Prasad DV, Suzuki K, Ishii M, Terai K, Moriya M, Nakatsuji Y, Sakoda S, Sato S, Akira S, Takeda K, Inui M, Takai T, Ikawa M, Okabe M, Kumanogoh A, Kitani H. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol 2006; 8: 615-622

39 Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Lifante C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765

40 Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichtinister M, Yamae Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Danse R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139

41 Cohen SB, Dore RK, Lane NE, Ory PA, Peterly CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-1309

42 Sen M, Lauterbach K, El-Gabalawy H, Firestein GS, Corr M, Carson DA. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97: 2791-2796

43 Sen M, Chamorro M, Reifert J, Corr M, Carson DA. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 2001; 44: 772-781

S- Editor Huang XZ  L- Editor A  E- Editor Xiong L